🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. FOG-001

    Parabilis Medicines

    Cancer

    phase 2 small molecule active

    1 trial

  2. FOLFOX/FOLFIRI

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unresectable or Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  3. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  4. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  5. FOLINIC ACID, FLUOROURACIL, BEVACIZUMAB, Telisotuzumab adizutecan, FOLINIC ACID, PANITUMUMAB, OXALIPLATIN

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  6. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  7. FRUZAQLA 5 mg hard capsules, Tevimbra 100 mg concentrate for solution for infusion, FRUZAQLA 1 mg hard capsules, Lonsurf 15 mg/6.14 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic Colorectal Cancer without liver metastases

    phase 2 small molecule active

    1 trial

  8. FULVESTRANT, camizestrant, camizestrant

    AstraZeneca AB

    Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Fasiglifam

    Takeda

    Type 2 Diabetes Mellitus

    phase 2 small molecule terminated

    2 trials

  10. Felzartamab

    Biogen

    Immunoglobulin A (IgA) Nephropathy

    phase 2 small molecule completed

    1 trial

  11. Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

    Biogen

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  12. Fentanyl Buccal Tablet

    Teva Pharma GmbH

    Advanced Cancers

    phase 2 small molecule completed

    1 trial

  13. Fianlimab

    Regeneron UK Limited

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  14. Fianlimab

    Regeneron UK Limited

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. Fianlimab

    Regeneron UK Limited

    Advanced Renal Cell Carcinoma (aRCC)

    phase 2 small molecule active

    1 trial

  16. Fianlimab+cemiplimab

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  17. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Pleural mesothelioma

    phase 2 small molecule active

    1 trial

  18. Fianlimab, LIBTAYO 350 mg concentrate for solution for infusion.

    Disc Medicine

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    phase 2 small molecule active

    1 trial

  19. Fibromun, Dacarbazine medac 1000 mg, powder for solution for infusion

    Philogen S.p.A.

    Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.

    phase 2 small molecule active

    1 trial

  20. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  21. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  22. Film-coated placebo to match estetrol monohydrate (E4) 20mg tablet

    Estetra SPRL

    postmenopausal women with vasomotor menopausal symptoms

    phase 2 small molecule active

    1 trial

  23. Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc, Fipaxalparant

    Elan Pharma International

    Diffuse Cutaneous Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  24. Fipaxalparant, Film-coated tablet, Major Ingredients Mannitol, microcrystalline cellulose, magnesium stearate, polyvinyl alcohol, macrogol, titanium dioxide and talc

    Elan Pharma International

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources